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Point-of-Care Virologic Testing to Improve Outcomes of
HIV-Infected Children in Zambia: A Clinical Trial Protocol
Carla J. Chibwesha, MD, MSc,*† Catherine E. Ford, MD, MPH,*† Katie R. Mollan, MS,‡
and Jeffrey S. A. Stringer, MD*
Introduction: In the absence of early infant diagnosis (EID) and
immediate antiretroviral therapy (ART), some 50% of untreated HIV-
infected infants die before age 2. Conventional EID requires sophis-
ticated instruments that are typically placed in centralized or reference
laboratories. In low-resource settings, centralized systems often lead to
result turnaround times of several months, long delays in diagnosis, and
adverse outcomes for HIV-infected children. Our clinical trial tests the
effectiveness of a new point-of-care (POC) diagnostic technology to
identify HIV-infected infants and start providing them life-saving ART
as soon as possible.
Methods and Design: The study uses a randomized, controlled
design to test whether the Alere q platform for HIV DNA polymerase
chain reaction (PCR) testing improves outcomes of HIV-infected
children in Zambia. We aim to enroll 2867 HIV-exposed infants aged
4–12 weeks and to follow those who are HIV infected for 12 months
as they receive HIV care at 6 public health facilities in Lusaka. The
trial’s primary endpoint is the proportion of HIV-infected infants in
each study arm who start ART and remain alive, in care, and virally
suppressed 12 months after their diagnostic blood draw.
Discussion: Our trial will provide evidence for the incremental
benefit of implementing a POC EID strategy in low-resource settings
where only off-site PCR services are currently available. The results
will be useful in guiding future decisions regarding investments in
POC virologic testing as part of overall pediatric AIDS mitigation
strategies in sub-Saharan Africa.
Trial Registration: clinicaltrials.gov NCT02682810.
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INTRODUCTION
Despite recent advances in prevention science, pediatric
AIDS remains an important public health problem in many
countries with high HIV burden. In 2014, an estimated
170,000 children were newly infected with HIV.1 Mother-
to-child transmission is responsible for the majority of these
pediatric infections and can be prevented with antiretroviral
therapy (ART). Yet, in many settings, the coverage of
prevention interventions remains suboptimal.2–5 When ART
or antiretroviral prophylaxis is not provided (or fails), early
infant diagnosis (EID) and immediate initiation of ART
become critical because HIV infection progresses rapidly in
infants.6
It is well established that early ART has a profound
survival effect,6–8 and WHO guidelines recommend that ART
be initiated in HIV-infected infants as soon as possible after
diagnosis.9 Despite this global recommendation, however, the
majority of HIV-infected children in sub-Saharan Africa
(SSA) never start treatment.1 An important reason for this
failure lies in the complexity of EID. Most national programs
use HIV DNA polymerase chain reaction (PCR) assays for
infant diagnosis, a sophisticated technology that is best suited
for high-volume, centralized laboratories. In a typical pro-
gram, dried blood spot (DBS) specimens are obtained and
transported from peripheral locations to a centralized labora-
tory. This logistically challenging arrangement can result in
delays of many weeks or months before results are returned to
patients and can also contribute to results being lost during
sample and data transfer. In the meantime, children may
become lost to follow-up (LTFU). In Malawi, for example,
delays between collection of the blood sample and parents’
receipt of their infant’s HIV test results were identified as
a major cause of pediatric HIV program attrition.10 The
challenges are similar in Zambia, where only 4 public-sector
laboratories currently perform HIV DNA PCR testing
for EID.
Alere q Detect Qualitative Test for EID is a point-of-
care (POC) nucleic acid testing platform that is suitable for
placement in low-volume and remote settings.11,12 Results are
available within 1 hour, which allows reporting of results on
the same day. Clinical performance of the Alere q was
recently validated in Mozambique in a study that included
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heel-stick samples from 827 HIV-exposed infants. The
prevalence of HIV among infants in this study was 7.9%.
Gold standard testing was performed using the Roche
COBAS Ampliprep/Taqman system. The sensitivity of Alere
q was reported as 98.5% [95% confidence interval (CI):
91.7% to 99.9%] and the specificity as 99.9% (95% CI:
99.3% to 100%). The positive and negative predictive values
for the test were also high [98.5 (95% CI: 96.3% to 100%)
and 99.9% (95% CI: 99.7% to 100%), respectively].13
In this article, we present the study protocol for
randomized, clinical trial that tests the field effectiveness of
Alere q as a tool to improve outcomes of HIV-infected
children in Zambia. HIV-exposed infants are randomized to
receive their diagnosis either using Alere q or using the usual
standard of off-site PCR. Our primary hypothesis is that HIV-
infected children who receive their diagnosis using the Alere
q POC test will be more likely to start ART and to remain
alive, in care, with suppressed HIV plasma viral load 12
months after their diagnostic blood draw, compared with
those who are randomized to receive a diagnosis using the
current standard for EID.
METHODS AND DESIGN
Study Design
Our study is an unmasked, randomized, controlled trial.
Participating HIV-exposed infants are randomly assigned to
receive either (1) standard, off-site EID through HIV DNA
PCR testing of DBS samples or (2) POC EID using the Alere q
HIV Detect test. Following the principles of a “pragmatic
trial,” our intervention is overlaid on the background of routine
clinical practice, with minimal protocol-related constraints,
liberal inclusion criteria, and few exclusion criteria.14,15 The
study is being conducted in prevention of mother-to-child
transmission and pediatric ART clinics at 6 participating public
health facilities in Lusaka, Zambia. These study sites were
selected because the volume of HIV-exposed infants receiving
EID services at each site is .100 infants per year.
Study Participants
To be eligible for inclusion, infants are between the
ages of 4 and 12 weeks of life and have HIV exposure
documented by a seropositive maternal or infant HIV
antibody test. To align the trial population with what would
be expected in a real-world implementation of this technol-
ogy, we have elected to exclude infants with major congenital
anomalies or other medical conditions that require manage-
ment at a referral facility. We also excluded those whose
parents/guardians are unwilling to provide written consent for
study participation.
Intervention
The trial includes 2 study arms: a standard of care
(SOC) or control arm and an intervention arm. In both study
arms, EID is provided at ;6 weeks of life. Infants
randomized to the SOC arm receive EID through the extant
public-sector EID program in Lusaka, with DBS samples sent
to an off-site laboratory for DNA PCR testing. Infants
randomized to the intervention arm receive POC Alere q
testing along with a DBS drawn for confirmatory off-site
DNA PCR testing of Alere q positive results.
Primary Objective
The main objective of our trial is to determine whether
POC virologic testing improves clinical outcomes of HIV-
infected children in Zambia. We define an ideal outcome as
being alive, retained in care, receiving ART, and having
a suppressed viral load, and we have designed the study to
measure this composite.
Study Procedures
In Zambia, EID is provided at 6 weeks of life and
corresponds with the infant’s initial vaccination visit. During
this routine visit, study personnel approach parents/guardians
of potential participants to determine eligibility for enroll-
ment. Research personnel describe the study and obtain
written informed consent for study enrollment from care-
givers of eligible participants.
Eligible infants are randomly allocated to 1 of 2 study
arms in a 1:1 ratio. Infants randomly assigned to the SOC arm
have a blood specimen drawn for DNA PCR testing and are
asked to return to clinic within 4 weeks to receive the result.
Positive DBS results are confirmed with a second test, in
keeping with national guidelines. Infants randomly assigned
to the intervention arm receive POC EID testing using the
Alere q HIV Detect test. Those who are Alere q positive are
immediately enrolled into the ART program with ART
initiated as soon as possible. Once again, all positive tests
are confirmed with a second test.
All HIV-infected infants are initiated on a lopinavir/
ritonavir-based regimen16 and followed in the government
clinics with monthly follow-up visits during the first year on
ART. Their care is provided by clinic staff and includes physical
examinations, laboratory monitoring, and basic adherence
counseling. ART is provided through the existing government
treatment programs. Current Zambian guidelines also recom-
mend viral load monitoring 3 times during the first year of
treatment (at 6, 9, and 12 months) and annually thereafter,
although this schedule is not always followed in real practice.
After ART initiation, 3 additional follow-up study visits
are scheduled for the infants at 3, 6, and 12 months (Tables 1
and 2). Per study protocol, all infants undergo plasma HIV
viral load testing at 12 months to measure the primary
outcome. If at any time during follow-up there is clinical or
laboratory evidence of virologic failure, participants are
referred for intensive adherence counseling with clinical
changes made in accordance with local guidelines for
management of virologic failure in pediatric populations.
Laboratory Testing
For HIV DNA PCR testing, five 75–100 mL DBS
aliquots are prepared on a Whatman 903 collection card (GE
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Healthcare Bio-Sciences Corporation, Piscataway, NJ) using
a heel-stick, whole-blood sample. Appropriately labeled DBS
cards are then transported to the central laboratory in a sealed
bag containing desiccant. DBS samples are tested using the
Roche COBAS Ampliprep/Taqman Qualitative HIV-1 Test
v2.0 (Roche Molecular Diagnostics, Pleasanton, CA) in
accordance with the manufacturer’s recommendations. We
designed the study to ensure that all infants receive their initial
HIV test result within 4 weeks of their blood being drawn, and
use a commercial laboratory if DBS test results are not
available from the routine central laboratory within 3 weeks.
The Alere q Detect Qualitative Test (Alere Technolo-
gies, Jena, Germany) is performed using 25 mL of whole
blood, collected through heel-stick and performed according
to the manufacturer’s instructions. The test has been opti-
mized for HIV groups prevalent in SSA, including HIV-1
groups M, N, and O and HIV-2. All test reagents are
contained within a single-use cartridge, and no pretreatment
(or other handling) of the sample is required. PCR amplifi-
cation and real-time fluorescence detection are performed
using a small, bench-top analyzer.11,12 The turnaround time is
approximately 1 hour, and the test is performed in the
study clinic.
As noted above, positive DBS tests are repeated and
positive Alere q tests are confirmed through DBS testing.
Although we expect discrepancies between the Alere q and
Roche EID tests to be rare,13 we have developed a 2-step
algorithm to resolve any such discrepancies. For discordant
results, we repeat both the Alere q and Roche EID tests using
fresh samples, and obtain 3 additional 75–100 mL DBS
aliquots. If the discrepancy persists, we perform Abbott
m2000 HIV Qualitative PCR testing (using remaining DBS
aliquots), which serves as a “tie-breaker” between the Alere q
and Roche tests. This algorithm ensures that the HIV status of
every randomized infant is determined definitively.
HIV-1 plasma viral load testing is also performed using
the Roche Cobas Ampliprep/Taqman platform (Roche Molec-
ular Diagnostics). Plasma is isolated from whole-blood
samples, and then processed and tested in a central laboratory
according to the manufacturers’ recommendations.
Primary Endpoint
The primary endpoint is the proportion of HIV-infected
children who initiate ART and remain in care with suppressed
plasma viral load (#200 copies/mL) 12 months after their
diagnostic blood draw. This composite outcome is designed
to measure the overall effectiveness of the intervention.
Sample Size
We postulate that the availability of same-day POC EID
will improve ART initiation from 40% to 80% and improve
viral suppression at 12 months from 80% to 90%. We also
postulate equally in both study arms that 72% of children will
be alive and in care by 12 months, with 22% LTFU and 6%
deceased by 12 months.17 Applying these estimates as
conditional probabilities, we anticipate a success rate of
0.23 in the SOC arm and 0.52 in the intervention arm.
Assuming 12-month success probabilities of 23% in the SOC
arm and 52% in the intervention arm, a sample size of 86
HIV-infected children (43 per arm) provides 80% power to
detect a difference in success probability between arms using
a x2 test with 2-sided alpha of 0.05 (SAS power procedure,
SAS version 9.3, Cary, NC). Given an expected mother-to-
child transmission rate of 3%,1 we aim to enroll 2867 HIV-
exposed infants to identify 86 infected infants for follow-up.
TABLE 1. Schedule of Events in the Control Arm
Evaluation
Visit
1
Visit
2
Visit
3
Visit
4
Visit
5
Visit
6
Informed consent ✓
Documentation of HIV
exposure
✓
EID blood draw ✓
EID test result given ✓
ART enrollment* ✓
CD4+ cell count* ✓ ✓ ✓
Clinical assessment* ✓ ✓ ✓ ✓ ✓
Adherence counseling* ✓ ✓ ✓ ✓
Adherence assessment* ✓ ✓ ✓
Confirmatory EID result* ✓
ART initiation* ✓
Routine clinical laboratory
tests (hematology, liver
function, and kidney
function)*
✓ ✓ ✓ ✓
HIV-1 plasma viral load* ✓ ✓
Stored dried blood spots ✓
Stored plasma specimens* ✓ ✓ ✓
*Performed among HIV-infected infants; HIV-uninfected infants exited at visit 2.
TABLE 2. Schedule of Events in the Intervention Arm
Evaluation
Visit
1
Visit
2
Visit
3
Visit
4
Visit
5
Informed consent ✓
Documentation of HIV exposure ✓
EID blood draw ✓
EID test result given ✓
ART enrollment* ✓
CD4+ cell count/percent* ✓ ✓ ✓
Clinical assessment* ✓ ✓ ✓ ✓
Adherence counseling* ✓ ✓ ✓ ✓
Adherence assessment* ✓ ✓ ✓
Confirmatory EID result* ✓
ART initiation* ✓
Routine clinical laboratory tests
(hematology, liver function, and
kidney function)*
✓ ✓ ✓ ✓
HIV-1 plasma viral load* ✓ ✓
Stored dried blood spots ✓
Stored plasma specimens* ✓ ✓ ✓
*Performed among HIV-infected infants; HIV-uninfected infants exited at visit 1.
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Children who are confirmed uninfected are exited from the
study and not followed for the 12 months.
Statistical Analysis
Descriptive statistics will be used to delineate the
overall study population and assess for clinically meaningful
imbalances between the intervention and SOC arms. The
primary endpoint (proportion who are in care and virally
suppressed at 12 months) will be evaluated among HIV-
infected participants and compared between the intervention
arm and SOC arm using an estimated risk ratio and
corresponding 95% Wald confidence interval. HIV infection
status at the time of randomization will be ascertained for all
infants such that the subset of HIV-infected infants can be
fully identified.
A sensitivity analysis will be conducted using a log-
binomial model18 to estimate a risk ratio adjusted for
prespecified possible confounders that, if unbalanced in the
2 arms, could potentially bias the estimate of effect.
Prespecified possible confounders include infant birth weight,
CD4+ percentage at ART commencement, presence of
clinical AIDS, and maternal vital status.
In a secondary analysis among all enrolled infants
(anticipated n = 2867), the HIV transmission proportion in
this study population will be estimated with a corresponding
Clopper and Pearson 95% CI. All statistical analyses will be
conducted using a 2-sided 0.05 significance level.
Ethical Considerations
Participation in the trial is voluntary, and caregivers of
study participants provide written, informed consent before
study enrollment. All procedures are conducted in accordance
with local SOC. The study protocol has been reviewed and
approved by the University of Zambia’s Biomedical Research
Ethics Committee, the Zambian Ministry of Health, and the
University of North Carolina at Chapel Hill’s Institutional
Review Board. All staff who have contact with participants
receive training on the protection of human research partic-
ipants before conducting any study activities and every 2
years thereafter. Key staff also complete Good Clinical
Practice or Good Clinical Laboratory Practice training.
Risks to participants in this study are minimal and do
not differ significantly from the risks inherent in the local
SOC for HIV-infected infants, with the exception of the
additional risks to participant confidentiality and data privacy.
Study participation may also cause stigmatization or discrim-
ination against participants and their families. The confiden-
tiality of all study records is safeguarded to the extent legally
possible, and all laboratory specimens, reports, study data,
and administrative forms are identified by a coded number
only. Databases are also secured with password-protected
access systems.
Participants in the intervention arm may benefit from
POC HIV diagnosis and more timely initiation of ART. The
knowledge generated from this study regarding the potential
benefits of the Alere q platform and the feasibility of its
implementation will enable the Zambian Ministry of Health to
make evidence-based decisions regarding POC assays
for EID.
DISCUSSION
Unlike HIV testing in adults, diagnosis in infants
requires specialized laboratory equipment, traditionally oper-
ated by personnel available only in central laboratories. As
a result, many infants either have no access to HIV diagnosis at
all or must wait for weeks or months to receive their test result.
In Zambia—as in many countries in the region—treatment is
never started for more than half of newborns who are tested
and found to be infected.1 A POC assay for early infant HIV
diagnosis may offer a distinct advantage over the current
standard clinical practice of off-site PCR in SSA. The POC
platform, Alere q, was designed specifically for near-patient
use in resource-poor settings, as the instrument is portable,
battery-operated, and ruggedized. The Alere q test has also
been optimized for HIV groups prevalent in SSA.
This trial will be the first of its kind in Zambia, and our
composite primary outcome is designed to measure the
incremental effectiveness of the intervention when compared
with the usual standard, thus providing key estimates for policy
makers who must decide whether or not to make substantial
countrywide investments in POC technologies in the future.
The composite outcome measure accounts for the immediate
effect of the POC technology on ART initiation and any
potential effect on remaining in care with virologic suppres-
sion. We have chosen to link these outcomes into a composite
because we believe that they are inextricably linked in real
practice. The POC technology may very well increase the
proportion of infants who start ART immediately, but this early
“win” could be diluted by higher rates of LTFU.
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